BR9910504A - Agonistas e antagonistas seletivos de il-2 - Google Patents

Agonistas e antagonistas seletivos de il-2

Info

Publication number
BR9910504A
BR9910504A BR9910504-7A BR9910504A BR9910504A BR 9910504 A BR9910504 A BR 9910504A BR 9910504 A BR9910504 A BR 9910504A BR 9910504 A BR9910504 A BR 9910504A
Authority
BR
Brazil
Prior art keywords
antagonists
muteins
cells
human
agonists
Prior art date
Application number
BR9910504-7A
Other languages
English (en)
Other versions
BRPI9910504B1 (pt
Inventor
Armen B Shanafelt
Jeffrey M Greve
Gary Jesmok
Kenneth J Lembach
Gayle D Wetzel
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR9910504A publication Critical patent/BR9910504A/pt
Publication of BRPI9910504B1 publication Critical patent/BRPI9910504B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Patente de Invenção: <B>"AGONISTAS E ANTAGONISTAS SELETIVOS DE IL-2"<D>. A invenção é direcionada a um polipeptídeo compreendendo uma muteína de IL-2 humana numerada de acordo com a IL-2 do tipo silvestre onde a referida IL-2 humana é substituída em pelo menos uma das posições 20, 88 ou 126, por meio das quais a referida muteína preferivelmente ativa as células T sobre as células NK. D20H e I. N88G, I e R, em particular têm uma atividade diferencial de célula T relativa, muito maior do que a IL-2 nativa, com predita toxidade in vivo reduzida associada. A invenção também inclui polinucleotídeos codificando para as muteínas da invenção, vetores contendo os polinucleotídeos, células hospedeiras transformadas, composições farmacêuticas compreendendo as muteínas e métodos terapêuticos de tratamento.
BRPI9910504A 1998-05-15 1999-05-13 polipeptídeos agonistas e antagonistas seletivos de il-2, polinucleotideos que os codificam, composição farmacêutica contendo os referidos polipeptídeos, vetor e célula hospedeira BRPI9910504B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8008098A 1998-05-15 1998-05-15
PCT/US1999/010643 WO1999060128A1 (en) 1998-05-15 1999-05-13 Il-2 selective agonists and antagonists

Publications (2)

Publication Number Publication Date
BR9910504A true BR9910504A (pt) 2001-01-09
BRPI9910504B1 BRPI9910504B1 (pt) 2016-08-09

Family

ID=22155135

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9910504A BRPI9910504B1 (pt) 1998-05-15 1999-05-13 polipeptídeos agonistas e antagonistas seletivos de il-2, polinucleotideos que os codificam, composição farmacêutica contendo os referidos polipeptídeos, vetor e célula hospedeira

Country Status (39)

Country Link
EP (1) EP1076704B1 (pt)
JP (1) JP4276783B2 (pt)
KR (1) KR100607609B1 (pt)
CN (2) CN101319247B (pt)
AR (1) AR020322A1 (pt)
AT (1) ATE351907T1 (pt)
AU (1) AU759697B2 (pt)
BG (1) BG65139B1 (pt)
BR (1) BRPI9910504B1 (pt)
CA (1) CA2327349C (pt)
CO (1) CO5070701A1 (pt)
CU (2) CU23273B7 (pt)
CY (1) CY1107533T1 (pt)
CZ (1) CZ302071B6 (pt)
DE (1) DE69934881T2 (pt)
DK (1) DK1076704T3 (pt)
DZ (1) DZ2788A1 (pt)
ES (1) ES2281175T3 (pt)
HK (1) HK1039963B (pt)
HN (1) HN1999000075A (pt)
HU (1) HU226142B1 (pt)
IL (2) IL139136A0 (pt)
MY (1) MY130274A (pt)
NO (1) NO329235B1 (pt)
NZ (1) NZ508098A (pt)
PA (1) PA8472601A1 (pt)
PE (1) PE20000475A1 (pt)
PL (1) PL201675B1 (pt)
PT (1) PT1076704E (pt)
RO (1) RO122150B1 (pt)
RU (1) RU2235729C2 (pt)
SI (1) SI20643B (pt)
SK (1) SK288100B6 (pt)
SV (1) SV1999000061A (pt)
TN (1) TNSN99090A1 (pt)
TR (1) TR200003354T2 (pt)
TW (1) TWI223663B (pt)
UA (1) UA73719C2 (pt)
WO (1) WO1999060128A1 (pt)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4057300A (en) * 1999-03-30 2000-10-16 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinacious compounds
EP1935431A3 (en) 2000-05-15 2008-08-13 Health Research, Inc. Cancer treatments by using a combination of an antibody against her2 and interleukin-2
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
MY139948A (en) * 2000-09-28 2009-11-30 Bayer Corp Enhanced transfection system
US7723102B2 (en) * 2000-09-28 2010-05-25 Bayer Corporation Enhanced transfection system
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
AU2002357784B2 (en) 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
DK1944318T3 (da) 2003-07-21 2011-06-14 Transgene Sa Multifunktionelle cytokiner
ATE447412T1 (de) 2003-11-04 2009-11-15 Novartis Vaccines & Diagnostic Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
JP5744369B2 (ja) * 2004-02-27 2015-07-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ＩＬ１５−Ｒα用ＩＬ−１５結合部位およびアゴニスト／アンタゴニスト活性を有する特異的ＩＬ−１５突然変異体
BRPI0508470A (pt) * 2004-03-05 2007-07-31 Chiron Corp sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
WO2009061853A2 (en) * 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
CN101244261B (zh) * 2008-03-10 2010-09-15 山东大学 一种含未复性重组蛋白的生物制剂及其制备方法与应用
DE102008023820A1 (de) * 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
MX2011007647A (es) 2009-01-21 2011-09-01 Amgen Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
CN102101885B (zh) * 2010-09-01 2013-06-05 南京发士达生物科技有限公司 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
RS61854B1 (sr) 2010-11-12 2021-06-30 Nektar Therapeutics Konjugati il-2 dela i polimera
JP6093712B2 (ja) * 2010-12-22 2017-03-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン２のスーパーアゴニストおよびアンタゴニスト
SI2673294T1 (sl) 2011-02-10 2016-08-31 Roche Glycart Ag Mutirani polipeptidi interlevkina-2
WO2012119093A1 (en) * 2011-03-03 2012-09-07 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
JP2016533167A (ja) 2013-09-24 2016-10-27 メディシナ セラピューティクス ピーティーイー リミテッド インターロイキン−２融合タンパク質及びその使用
KR20190126205A (ko) 2014-02-06 2019-11-08 에프. 호프만-라 로슈 아게 인터류킨-2 융합 단백질 및 이의 용도
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3134102B1 (en) 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
JP6640834B2 (ja) * 2014-08-11 2020-02-05 デリニア， インコーポレイテッド 自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
WO2017201432A2 (en) * 2016-05-19 2017-11-23 Jounaidi Youssef Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2017220988A1 (en) 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
AU2017281469B2 (en) * 2016-06-22 2023-08-31 David Klatzmann Genetically modified T lymphocytes
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018089420A1 (en) 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases
US10472405B2 (en) * 2016-12-13 2019-11-12 Delinia, Inc. Multivalent regulatory T cell modulators
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
BR112019024127A2 (pt) 2017-05-24 2020-06-23 Pandion Therapeutics, Inc. Imunotolerância alvejada
US12006354B2 (en) 2017-05-24 2024-06-11 Novartis Ag Antibody-IL2 engrafted proteins and methods of use in the treatment of cancer
US20200362058A1 (en) * 2017-05-24 2020-11-19 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
CN111201035A (zh) 2017-06-19 2020-05-26 梅迪塞纳医疗股份有限公司 Il-2超激动剂、激动剂及其融合体的用途和方法
NZ761430A (en) * 2017-08-03 2024-03-22 Synthorx Inc Cytokine conjugates for the treatment of proliferative and infectious diseases
EP3713592A4 (en) * 2017-11-21 2022-01-12 The Board of Trustees of the Leland Stanford Junior University INTERLEUKIN-2 PARTIAL AGONISTS
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
US11534479B2 (en) 2018-02-16 2022-12-27 Iltoo Pharma Use of interleukin 2 for treating Sjögren's syndrome
PE20210313A1 (es) 2018-03-28 2021-02-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
CA3093722A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma Oncology Division A/S Il-2 conjugates
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
BR112021000811A8 (pt) * 2018-07-24 2022-10-18 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Agonistas de il2
EP3836954A1 (en) 2018-08-13 2021-06-23 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
BR112020015030A2 (pt) * 2018-09-17 2021-03-16 Gi Innovation, Inc. Proteína de fusão compreendendo a proteína il-2 e a proteína cd80 e uso da mesma
KR20210107714A (ko) 2018-12-21 2021-09-01 지앙수 헨그루이 메디슨 컴퍼니 리미티드 인간 인터류킨-2 변이체 또는 이의 유도체
JP2022533702A (ja) 2019-05-20 2022-07-25 パンディオン・オペレーションズ・インコーポレイテッド ＭＡｄＣＡＭ標的化免疫寛容
TW202115105A (zh) * 2019-06-24 2021-04-16 德商拜恩迪克Ｒｎａ製藥有限公司 Ｉｌ２激動劑
CR20220111A (es) * 2019-08-13 2022-05-04 Amgen Inc Muteínas de interleucina-2 para la expansión de células t reguladoras referencia cruzada a solicitudes relacionadas
JP2023505590A (ja) 2019-12-12 2023-02-09 イルトゥー・ファルマ インターロイキン２キメラ構築物
CN114867749A (zh) 2019-12-17 2022-08-05 安进公司 用于疗法中的双重白介素-2/tnf受体激动剂
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
US11491205B2 (en) 2020-01-14 2022-11-08 Synthekine, Inc. Biased IL2 muteins methods and compositions
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
CN115698052A (zh) 2020-03-19 2023-02-03 信达生物制药(苏州)有限公司 白介素2突变体及其用途
CA3169564A1 (en) * 2020-03-31 2021-10-07 Hanmi Pharm. Co., Ltd. Novel immunostimulating il-2 analogs
CA3178074A1 (en) 2020-06-03 2021-12-09 Nina Gunnarsson Il-2 sequences and uses thereof
CN114507643A (zh) * 2020-10-29 2022-05-17 未来智人再生医学研究院(广州)有限公司 一种表达il-2的多能干细胞衍生物及应用
CA3195260A1 (en) 2020-10-29 2022-05-05 Bristol-Myers Squibb Company Fusion proteins for the treatment of disease
CN113308477A (zh) * 2021-04-08 2021-08-27 华南农业大学 一种鸭il-2基因真核表达重组质粒及其制备方法
WO2023045977A1 (zh) 2021-09-22 2023-03-30 信达生物制药(苏州)有限公司 白介素2突变体以及其融合蛋白
AU2022360645A1 (en) 2021-10-06 2024-05-02 Assistance Publique - Hôpitaux De Paris Interleukin 2 chimeric constructs with targeting specificity to inflamed tissues
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
TW202413442A (zh) * 2022-06-16 2024-04-01 美商希佛隆有限責任公司 抗pd-1抗體減弱之il-2免疫結合物及其用途
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder
FR3140287A1 (fr) 2022-10-03 2024-04-05 Arkema France Procede de granulation de composes azoiques et granules obtenus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13

Also Published As

Publication number Publication date
HUP0101948A2 (hu) 2001-09-28
HK1039963B (zh) 2008-09-05
HN1999000075A (es) 1999-09-29
EP1076704A1 (en) 2001-02-21
SI20643B (sl) 2008-02-29
CA2327349A1 (en) 1999-11-25
PL201675B1 (pl) 2009-04-30
BG65139B1 (bg) 2007-03-30
TR200003354T2 (tr) 2001-03-21
SK288100B6 (sk) 2013-07-02
PL344407A1 (en) 2001-11-05
EP1076704B1 (en) 2007-01-17
CY1107533T1 (el) 2013-03-13
ATE351907T1 (de) 2007-02-15
HK1039963A1 (en) 2002-05-17
ES2281175T3 (es) 2007-09-16
SI20643A (sl) 2002-02-28
CN101319247B (zh) 2012-12-12
IL139136A0 (en) 2001-11-25
KR20010043602A (ko) 2001-05-25
KR100607609B1 (ko) 2006-08-02
NO20005762D0 (no) 2000-11-14
DE69934881T2 (de) 2007-11-08
NZ508098A (en) 2003-09-26
DZ2788A1 (fr) 2003-12-01
SK17242000A3 (sk) 2001-07-10
JP2002515247A (ja) 2002-05-28
RU2235729C2 (ru) 2004-09-10
CZ302071B6 (cs) 2010-09-29
AU759697B2 (en) 2003-04-17
MY130274A (en) 2007-06-29
CU23272A1 (es) 2008-04-09
WO1999060128A1 (en) 1999-11-25
PA8472601A1 (es) 2000-09-29
DE69934881D1 (de) 2007-03-08
PE20000475A1 (es) 2000-07-07
CU23273B7 (es) 2008-04-09
CN101319247A (zh) 2008-12-10
TWI223663B (en) 2004-11-11
CN100366742C (zh) 2008-02-06
PT1076704E (pt) 2007-02-28
RO122150B1 (ro) 2009-01-30
BG104929A (en) 2001-09-28
DK1076704T3 (da) 2007-03-12
UA73719C2 (en) 2005-09-15
CA2327349C (en) 2010-10-26
HUP0101948A3 (en) 2003-08-28
TNSN99090A1 (fr) 2005-11-10
CZ20004213A3 (en) 2001-05-16
SV1999000061A (es) 2000-03-14
AU4078499A (en) 1999-12-06
AR020322A1 (es) 2002-05-08
NO329235B1 (no) 2010-09-20
HU226142B1 (en) 2008-05-28
BRPI9910504B1 (pt) 2016-08-09
CN1309705A (zh) 2001-08-22
IL139136A (en) 2009-05-04
JP4276783B2 (ja) 2009-06-10
CO5070701A1 (es) 2001-08-28
NO20005762L (no) 2001-01-11

Similar Documents

Publication Publication Date Title
BR9910504A (pt) Agonistas e antagonistas seletivos de il-2
BRPI0508424A (pt) muteìnas de interleucina-2 melhoradas
GT200000107A (es) Procedimiento para la obtencion de &#34;compuestos de indazol y composiciones farmaceuticas para inhibir las quinasas deproteina y metodos para su uso&#34;.
BR0207952A (pt) Moduladores da atividade de receptores de quimiocina
ATE114169T1 (de) Morphogenetisches knochenprotein.
ES2147553T3 (es) Vectores virales recombinantes para la expresion en unas celulas musculares.
FI953748A (fi) Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina
SE8102194L (sv) Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna
ES2150496T3 (es) Cicloalquilimidazopiridinas condensadas.
BRPI0410884A (pt) composição de ração para uso em um animal de estimação, e, método para o controle de peso em um animal de estimação
NO931141L (no) Tnf-muteiner
DK0579640T3 (da) Glialmitogene faktorer samt deres fremstilling og anvendelse
IT1298487B1 (it) Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
BR112022011975A2 (pt) Polipeptídeo de interferon-¿2 modificado, polipeptídeo gmop-interferon-¿2 modificado, ácido nucleico, plasmídeo, vetor, linha de célula, método para purificação do polipeptídeo de interferon-¿2 modificado, composição farmacêutica, método para uso de um ou mais dos polipeptídeos de interferon-¿2 modificados e método para tratar uma condição médica em um indivíduo
DE69705680D1 (de) Heterocyclische diarylverbindungen, sie enthaltende pharmazeutische und kosmetische zusammensetzungen, und ihre verwendung.
BR0206852A (pt) Conjugados de polìmero de neublastina e métodos para uso dos mesmos
BRPI0410470A (pt) uso de uma eritropoietina ou de uma citocina protetora de tecido e método para proteger ou manter a viabilidade de uma célula, tecido ou órgão de mamìfero respondente
BR9910585A (pt) Promotor de bmp-7 humano e método para explorar substância relacionada com os ossos usando o mesmo
DE69533796D1 (de) Für die glutamatabhängigen chloridkanäle kodierende dna
EA008938B1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
FR2680172B1 (fr) Nouvelles piperazinylalcoyl-3 dihydro-2,3 4h-benzoxazine-1,3 ones-4 substituees, leur preparation et leur application en therapeutique.
DK0902085T3 (da) Rekombinant human erythropoietin med fordelagtig glycosyleringsprofil
BR9812138A (pt) Métodos e composições para terapias empregando genes codificando proteìnas segregadas tal como interferon-beta
BR9709370A (pt) Gene semelhante a tolóide de mamìfero e proteìna.
WO2000065028A3 (en) TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: AICURIS GMBH AND CO. KG (DE)

Free format text: TRANSFERIDO DE: BAYER CORPORATION

B25G Requested change of headquarter approved

Owner name: AICURIS GMBH AND CO. KG (DE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020090023404/RJ DE 11/03/2009.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/08/2016, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 22A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2622 DE 06-04-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.